Engineered exosomes expressing SIRPα, PD-1, and LILRB1 interact with receptors on tumor cells (CD47, PD-L1, and B2M), promoting the phagocytosis of tumor cells and enhancing antigen presentation by immune cells [47]. Here, SIRPA is linked to neoplasm.